• LAST PRICE
    2.5900
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (1.1719%)
  • Bid / Lots
    2.5500/ 3
  • Ask / Lots
    2.7100/ 21
  • Open / Previous Close
    2.5500 / 2.5600
  • Day Range
    Low 2.5000
    High 2.6650
  • 52 Week Range
    Low 1.3200
    High 3.9700
  • Volume
    3,730,845
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 2.56
TimeVolumeLYEL
09:32 ET21482.5
09:34 ET2002.525
09:36 ET2082.54
09:38 ET1002.535
09:39 ET10102.55
09:41 ET8042.57
09:43 ET3032.575
09:45 ET10202.55
09:48 ET7392.565
09:50 ET7002.56
09:54 ET1002.56
09:56 ET2502.565
09:57 ET2202.565
09:59 ET1002.57
10:01 ET1002.565
10:03 ET17942.555
10:08 ET2132.56
10:10 ET6962.5525
10:12 ET8002.55
10:14 ET2162.545
10:15 ET6622.535
10:17 ET7002.53
10:19 ET9032.54
10:21 ET21902.545
10:24 ET2652.555
10:26 ET1002.56
10:30 ET1002.56
10:32 ET2922.555
10:33 ET4702.545
10:35 ET1013782.555
10:37 ET1002.555
10:39 ET6002.555
10:42 ET1002.55
10:44 ET14644302.555
10:46 ET61132.595
10:51 ET11662.61
10:55 ET7092.625
10:57 ET2002.625
11:00 ET2002.625
11:02 ET6502.636
11:04 ET9102.65
11:06 ET2002.64
11:08 ET5002.6599
11:09 ET7002.65
11:11 ET55002.64
11:13 ET9002.61
11:15 ET20262.605
11:18 ET8162.59
11:20 ET2002.59
11:22 ET3002.59
11:24 ET3542.59
11:26 ET13002.615
11:27 ET1002.615
11:29 ET9002.62
11:31 ET1002.62
11:36 ET28842.61
11:38 ET7002.61
11:40 ET9002.595
11:42 ET1002.59
11:44 ET3132.59
11:54 ET10002.58
11:56 ET3422.58
12:00 ET3002.575
12:02 ET8002.58
12:03 ET2002.575
12:16 ET2002.575
12:18 ET3002.575
12:20 ET30552.57
12:21 ET10015002.55
12:23 ET36812.53
12:25 ET8522.5209
12:27 ET27332.525
12:30 ET27602.53
12:32 ET4912.53
12:34 ET24402.555
12:38 ET6502.565
12:39 ET3002.5645
12:41 ET6692.575
12:43 ET2002.57
12:50 ET1002.57
12:52 ET10212.595
12:54 ET55002.595
12:56 ET1002.595
12:57 ET4002.59
12:59 ET1002.58
01:01 ET9492.565
01:03 ET4392.57
01:06 ET1323812.56
01:08 ET3902.56
01:10 ET5002.565
01:12 ET1002.565
01:14 ET2002.565
01:17 ET6002.555
01:19 ET1002.555
01:26 ET3672.565
01:30 ET1002.561
01:32 ET1002.565
01:37 ET7042.555
01:39 ET1002.555
01:42 ET3002.56
01:44 ET8472.56
01:46 ET1002.5675
01:53 ET4002.56
02:00 ET10002.555
02:04 ET1002.56
02:06 ET5422.56
02:09 ET1002.555
02:13 ET2002.55
02:15 ET1002.555
02:18 ET2002.55
02:20 ET13022.55
02:22 ET5096952.585
02:24 ET17542.6
02:31 ET1002.615
02:33 ET57002.63
02:36 ET1002.63
02:38 ET7002.64
02:42 ET10572.655
02:44 ET2002.655
02:45 ET54682.645
02:47 ET17002.64
02:51 ET9752.63
02:54 ET49432.63
02:56 ET1002.635
03:00 ET2002.635
03:02 ET6002.63
03:07 ET11002.635
03:09 ET3002.635
03:12 ET54002.665
03:14 ET2852.665
03:16 ET2132.665
03:18 ET6002.655
03:20 ET3002.66
03:21 ET25002.655
03:25 ET3002.65
03:27 ET142702.62
03:30 ET26342.615
03:32 ET6002.61
03:34 ET15902.6229
03:36 ET2002.62
03:38 ET42502.62
03:39 ET2002.62
03:41 ET5002.62
03:43 ET102502.62
03:45 ET20002.62
03:48 ET8002.62
03:50 ET6002.62
03:52 ET43332.62
03:54 ET1775212.62
03:56 ET66272.615
03:57 ET77592.605
03:59 ET205792.59
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLYEL
Lyell Immunopharma Inc
678.1M
-2.9x
---
United StatesLBPH
Longboard Pharmaceuticals Inc
696.0M
-8.9x
---
United StatesCOGT
Cogent Biosciences Inc
697.0M
-3.6x
---
United StatesGHRS
GH Research PLC
703.9M
-18.5x
---
United StatesAVBP
Arrivent Biopharma Inc
651.8M
0.0x
---
United StatesMREO
Mereo BioPharma Group PLC
503.6M
-15.0x
---
As of 2024-06-13

Company Information

Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The Company is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop medicines.

Contact Information

Headquarters
201 Haskins Way, Suite 301SOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-695-0677
Fax
302-531-3150

Executives

Chairman of the Board
Richard Klausner
President, Chief Executive Officer, Director
Lynn Seely
Chief Financial Officer
Charles Newton
Chief Operating Officer
Stephen Hill
Chief Scientific Officer
Gary Lee

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$678.1M
Revenue (TTM)
$68.0K
Shares Outstanding
254.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.91
Book Value
$2.58
P/E Ratio
-2.9x
Price/Sales (TTM)
9,972.6
Price/Cash Flow (TTM)
---
Operating Margin
-376,398.50%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.